Several trends have been witnessed within the healthcare industry in the quest for alternative ways to counteract microorganisms that cause illnesses. One of the trends includes the development of phage therapy. This is an approach that utilizes bacteriophages, which specifically kill bacteria. As the world grapples with cases of drug resistance and inefficiency of conventional antibiotics, the need to explore this form of therapy has been more pertinent than ever before.
Phage therapy is becoming popular owing to its precision nature. Since it involves using specific viruses to destroy disease-causing bacteria, it can be employed in dealing with multiple drug resistant bacteria.
The Phage Therapy Market Size is valued at USD 1.27 Billion in 2025 and is projected to reach USD 1.86 Billion by 2035, growing at a CAGR of 3.91% during the forecast period 2026–2035.
Leading Phage Therapy Companies Driving Market Innovation
Adaptive Phage Therapeutics
Adaptive Phage Therapeutics is concerned with the production of personalized solutions based on phage therapy against drug-resistant bacteria. The company uses large phage libraries and precise targeting techniques. It collaborates with clinical partners to develop hospital applications of the technique. Its research is highly related to antimicrobial resistance problems. The firm is currently involved in clinical stage development efforts.
Armata Pharmaceuticals
Armata Pharmaceuticals is a biotech company that concentrates on the development of genetically engineered phages used in treating infections caused by bacteria. The firm develops treatments for serious bacterial infections especially in hospital settings. Its focus is on validating and progressing with clinical stage development and regulatory approval of these treatments. The firm continues to build its pipeline of anti-infective products.
Locus Biosciences
Locus Biosciences designs CRISPR enhanced phages for bacteria that help in improving the efficiency of bacterial kill without developing any form of resistance. Locus Biosciences makes use of synthetic biology technologies coupled with phages to come up with new treatments. It is currently advancing its research programs in this area.
Intralytix, Inc.
Intralytix specializes in the development of phage technologies for use in food safety, clinic, and veterinary markets. The company uses bacteriophages for combating bacterial infections. These products have many applications in the food industry and infection control practices. The company continues to develop its product portfolio in the health care and industrial market segments.
Pherecydes Pharma
The company develops personalized treatments for difficult to treat bacterial infections using phage technology. This company works with hospitals in providing solutions to specific problems. Their main areas of specialization include the development of precise medicine and individualized treatment of bacterial infections.
Key Drivers Accelerating Adoption of Phage-Based Therapeutics
The key factors fueling the market demand for phage therapy are the ever-increasing threats of antibiotics being rendered ineffective due to the emergence of antibiotic resistance around the world. Phage therapy offers itself as a promising solution due to its highly specific nature that enables it to target certain strains of bacteria without interfering with the good ones.
One of the other drivers behind the growth of the market includes its growing utilization in the hospital, veterinary, and agricultural sectors. Clinically, it is used to treat infections that do not respond to antibiotics, while, on the other hand, in the agricultural sector, it finds application in the management of infections and ensuring bio-security.
Moreover, an increase in the number of research and development activities in this field is further aiding market growth. With healthcare institutions, academic bodies, and biotech companies focusing on developing their own phages to help treat diseases and fill gaps in treatments available today, the market continues to grow.
Additionally, there is an increased level of regulatory interest in bacteriophages as more trials are being conducted all around the world.
Exploring the Transformative Potential of Phage Therapy in Combating Antibiotic Resistance
According to market trends, there is a likelihood that the growth of the industry will be consistent because of the increased actions taken by health care systems to deal with the problem of antibiotic resistance. Within the organizations, focus will be placed on pipeline development, technological advancements, and collaboration with hospitals and research centers.
In view of the increasing demand for a tailored solution to treatment, phage therapy may become essential in complementing conventional treatment techniques.
Phage therapy is a radical departure from the current method of managing infectious diseases. In view of increasing resistance and increased studies, the market has potential for continued growth in the future.
